1. Home
  2. News
  3. Immuron Limited
  4. IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
More Immuron Limited news
Immuron LimitedASX: IMC

IMC and Calmino to treat Irritable Bowel Syndrome (IBS)

Mar 4, 2025 at 11:11 PM EST · Issued by Immuron Limited

Filed with ASX · Mar 4, 2025 at 11:11 PM EST · 2 pages · English

On 6ix: 6ix.com/news/imc-and-calmino-to-treat-irritable-bowel-syndrome-ibs

Immuron Limited on 6ix

In the deck

  • Immuron — Coffee Microcaps Conference 202515 slidesMar 7, 2025

Earlier from Immuron

  • Immuron Travelan continued strong sales growthJan 16, 2025
  • Immuron Announces Travelan Clinical Trial UpdateJan 14, 2025
  • NMRC Reports Results for Campylobacter Clinical StudyOct 4, 2024
  • Trading HaltOct 2, 2024
  • Immuron Plans Phase 2 Trial for IMM-529 following FDA reviewSep 5, 2024

Later from Immuron

  • Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)Mar 5, 2025
  • Immuron Travelan highest sales in historyApr 10, 2025
  • FY25 global sales exceed projection, up 49% on prior yearJul 16, 2025
  • Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live streamAug 19, 2025
  • Presenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamAug 20, 2025
All Immuron news releases↗

Follow Immuron into a list and get an email when it puts out news.

Follow Immuron
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer